GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

Sponsor
Genexine, Inc.
Study ID
NCT05191784
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • GX-I7 — DRUG
    Administered by intramuscular (IM) injection
  • Bevacizumab — DRUG
    Administered by intravenous (IV) injection

Study Details

The purpose of this study is to evaluate the efficacy and safety of GX-I7 in combination with bevacizumab in subjects with recurrent glioblastoma.

Key Dates

First listed
Jan 13, 2022
Start date
Jan 26, 2022
Status verified
Jun 2023
Primary completion
Dec 31, 2024
Completion
Dec 31, 2024

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: GX-I7 and bevacizumab
    Bevacizumab at a dose of 10 mg/kg intravenously, and GX-I7 intramuscularly.

Primary Outcome Measure

Progression free survival (PFS) [ Time Frame: From the initiation of study treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months. ]

Related Studies